3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow TrippBio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) PanCytoVir™ 100 mg/mL oral suspension, Probenecid 500 mg - Relative Bioavailability | Phase 1 | Completed | TrippBio, Inc. | 14 | 2024-09-01 | 2024-11-21 |
| An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers PanCytoVir™ - Relative Bioavailability | Phase 1 | Completed | TrippBio, Inc. | 14 | 2024-09-01 | 2024-11-21 |
| A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection PanCytoVir™ (probenecid), Placebo - COVID-19 | Phase 2 | Completed | TrippBio, Inc. | 75 | 2022-07-12 | 2023-08-25 |
COVID-19 (1)
Probenecid (2) · Suspensions (1)
India (3)